Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Allentown, PA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Allentown, PA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Philadelphia, PA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Charleston, SC
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Austin, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Bellaire, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Bellaire, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Dallas, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Fort Worth, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Houston, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Longview, TX
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Longview, TX
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Annandale, VA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Annandale, VA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Lynchburg, VA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Lynchburg, VA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Seattle, WA
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated:  1/28/2016
GSK Investigational Site
mi
from
Calgary,
A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen
201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.
Status: Enrolling
Updated: 1/28/2016
GSK Investigational Site
mi
from
Calgary,
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Harbor-UCLA Med. Ctr. CRS (603)
mi
from
Torrance, CA
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Washington University CRS (2101)
mi
from
St. Louis, MO
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Washington University CRS (2101)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Unc Aids Crs
mi
from
Chapel Hill, NC
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Duke Univ. Med. Ctr. Adult CRS (1601)
mi
from
Durham, NC
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Regional Center for Infectious Disease, Wendover Medical Center CRS (3203)
mi
from
Greensboro, NC
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Regional Center for Infectious Disease, Wendover Medical Center CRS (3203)
mi
from
Greensboro, NC
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
The Ohio State University AIDS CRS (2301)
mi
from
Colombus, OH
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
The Ohio State University AIDS CRS (2301)
mi
from
Colombus, OH
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated:  1/29/2016
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
A Randomized Controlled Trial to Compare the Effects of Highly Active Antiretroviral Therapy (HAART) Versus Statin Therapy on Endothelial Function and Markers of Inflammation/Coagulation In HIV-Infected Individuals With High CD4 Cell Counts
Status: Enrolling
Updated: 1/29/2016
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Alabama CRS
mi
from
Birmingham, AL
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Bridge HIV CRS
mi
from
San Francisco, CA
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Bridge HIV CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Hope Clinic of the Emory Vaccine Center CRS
mi
from
Decatur, GA
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Hope Clinic of the Emory Vaccine Center CRS
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Fenway Health (FH) CRS
mi
from
Boston, MA
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Columbia P&S CRS
mi
from
New York, NY
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Columbia P&S CRS
mi
from
New York, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
New York Blood Center CRS
mi
from
New York, NY
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
New York Blood Center CRS
mi
from
New York, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated:  2/1/2016
ACSA CRS
mi
from
Iquitos,
Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults
A Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of pGA2/JS7 DNA and MVA/HIV62, in Healthy, HIV Uninfected Vaccinia-naive Adult Participants
Status: Enrolling
Updated: 2/1/2016
ACSA CRS
mi
from
Iquitos,
Click here to add this to my saved trials
Text Messaging Intervention to Improve Retention in Care and Virologic Suppression in an Urban HIV-Infected Population
Seek Test Treat Retain Strategies Leveraging Mobile Health Technologies
Status: Enrolling
Updated:  2/1/2016
San Francisco General Hospital Positive Health Program
mi
from
San Francisco, CA
Text Messaging Intervention to Improve Retention in Care and Virologic Suppression in an Urban HIV-Infected Population
Seek Test Treat Retain Strategies Leveraging Mobile Health Technologies
Status: Enrolling
Updated: 2/1/2016
San Francisco General Hospital Positive Health Program
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated:  2/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated: 2/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated:  2/1/2016
Rockefeller University
mi
from
New York, NY
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated: 2/1/2016
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated:  2/1/2016
Weill Cornell Medical Center
mi
from
New York, NY
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated: 2/1/2016
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated:  2/1/2016
University of Cologne
mi
from
Cologne,
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117
A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers
Status: Enrolling
Updated: 2/1/2016
University of Cologne
mi
from
Cologne,
Click here to add this to my saved trials
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men
Status: Enrolling
Updated:  2/1/2016
Philadelphia FIGHT
mi
from
Philadelphia, PA
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men
Status: Enrolling
Updated: 2/1/2016
Philadelphia FIGHT
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  2/2/2016
Harlem Prevention Ctr. CRS
mi
from
New York, NY
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 2/2/2016
Harlem Prevention Ctr. CRS
mi
from
New York, NY
Click here to add this to my saved trials
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  2/2/2016
Emavundleni CRS
mi
from
Cape Town,
The ADAPT Study: Use of Emtricitabine and Tenofovir Disoproxil Fumarate for Pre-Exposure Prophylaxis (PrEP)
The ADAPT Study: A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis (PrEP) Pre-Exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 2/2/2016
Emavundleni CRS
mi
from
Cape Town,
Click here to add this to my saved trials
Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects
Pharmacokinetic Evaluation of Single-dose Rosuvastatin 10 mg When Co-administered With Steady-state Tipranavir 500 mg/Ritonavir 200 mg TPV/r) B.I.D. in Healthy Adult Volunteers
Status: Enrolling
Updated:  2/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects
Pharmacokinetic Evaluation of Single-dose Rosuvastatin 10 mg When Co-administered With Steady-state Tipranavir 500 mg/Ritonavir 200 mg TPV/r) B.I.D. in Healthy Adult Volunteers
Status: Enrolling
Updated: 2/2/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.
Status: Enrolling
Updated:  2/8/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System.
Status: Enrolling
Updated: 2/8/2016
George Washington University Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Immune and Viral Outcomes of HIV-1 Therapy Interruption
Immune and Viral Outcomes of HIV-1 Therapy Interruption
Status: Enrolling
Updated:  2/8/2016
The Wistar Institute
mi
from
Philadelphia, PA
Immune and Viral Outcomes of HIV-1 Therapy Interruption
Immune and Viral Outcomes of HIV-1 Therapy Interruption
Status: Enrolling
Updated: 2/8/2016
The Wistar Institute
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
A Study to Examine Immunological Response in HIV-Infected Patients Receiving the Seasonal Influenza Vaccine
Status: Enrolling
Updated:  2/8/2016
Medical Faculty Associates
mi
from
Washington,
Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
A Study to Examine Immunological Response in HIV-Infected Patients Receiving the Seasonal Influenza Vaccine
Status: Enrolling
Updated: 2/8/2016
Medical Faculty Associates
mi
from
Washington,
Click here to add this to my saved trials
Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM
Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM
Status: Enrolling
Updated:  2/9/2016
Columbia University School of Social Work
mi
from
New York, NY
Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM
Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM
Status: Enrolling
Updated: 2/9/2016
Columbia University School of Social Work
mi
from
New York, NY
Click here to add this to my saved trials
Vitamin D Supplements for HIV-positive Patients on cART
Vitamin D Supplements for HIV-positive Patients on cART
Status: Enrolling
Updated:  2/11/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Vitamin D Supplements for HIV-positive Patients on cART
Vitamin D Supplements for HIV-positive Patients on cART
Status: Enrolling
Updated: 2/11/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated:  2/12/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated: 2/12/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated:  2/12/2016
Carolinas Medical Center
mi
from
Charlotte, NC
Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection
Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection
Status: Enrolling
Updated: 2/12/2016
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials